Last Price
1.08
Today's Change
0.00 (0.00%)
Day's Change
1.06 - 1.10
Trading Volume
66,106
Profile
ADIL
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Cary John Claiborne MBA Mr. Cary John Claiborne MBA
Full Time Employees: 4 4
IPO Date: 2018-07-27 2018-07-27
CIK: 0001513525 0001513525
ISIN: US00688A2050 US00688A2050
CUSIP: 00688A106 00688A106
Beta: 1.30 1.30
Last Dividend: 0.00 0.00
Dcf Diff: -0.90 -0.90
Dcf: 1.98 1.98
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
2
CEO Morning Brief
US Producer Prices Pick Up Slightly After Downward Revisions
3
CEO Morning Brief
4
5
CEO Morning Brief
OpenAI Fundraising Set to Vault Startup’s Valuation to US$150b
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
